文献速递肝病

高血压对MASLD长期不良临床结局及肝纤维化进展的影响

Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD.
PubMed 文献 · J Hepatol · 2025-08-23

该研究基于三个大型多中心队列(UKBB、VCTE-Prognosis、配对肝活检队列)分析高血压与MASLD患者长期不良临床结局及肝纤维化进展的关联。结果显示高血压与不良临床结局(aHR 1.30)、肝硬度进展(aHR 1.57)及组织学纤维化进展(aHR 1.41)风险升高独立相关。高血压是MASLD中可干预的风险因素,应纳入肝病进展风险评估。

要点

  • 高血压与MASLD患者长期不良临床结局风险升高独立相关(aHR 1.30)。
  • 高血压与肝硬度进展(aHR 1.57)和组织学纤维化进展(aHR 1.41)风险升高相关。
  • 建议对MASLD合并高血压患者常规进行无创肝纤维化评估以早期风险分层。

核心结论

  • 高血压是MASLD患者不良临床结局及肝硬度/纤维化进展的可干预独立风险因素。

研究设计与样本

  • 研究分析三个多中心大型队列:UK Biobank队列(107,316名成人)评估不良临床结局风险,VCTE-Prognosis队列(8,169例)评估肝硬度/纤维化进展,配对肝活检队列(1,670例)评估组织学肝纤维化进展。
  • 不良临床结局定义为全因死亡、心血管事件和/或肝脏相关事件;肝硬度进展定义为肝硬度测量值从<10 kPa增至≥10 kPa或基线≥10 kPa者增加≥20%;肝纤维化进展定义为纤维化分期增加1期。
  • 采用Cox回归和Kaplan-Meier分析评估基线高血压对结局的影响。

主要发现

  • UKBB队列中高血压患病率为37.1%,VCTE-Prognosis队列为33.4%,配对肝活检队列为48.9%。
  • UKBB队列中高血压与长期不良临床结局相关(校正HR 1.30,95%CI 1.26-1.33,p<0.001)。
  • VCTE-Prognosis队列中高血压与肝硬度进展风险升高相关(校正HR 1.57,95%CI 1.30-1.90,p<0.001)。
  • 配对肝活检队列中高血压与组织学肝纤维化进展风险升高相关(校正HR 1.41,95%CI 1.12-1.78,p=0.004)。
  • 亚组和敏感性分析支持上述发现。

临床怎么用

  • 高血压传统上从心血管角度管理,但在MASLD患者中也应重视其对肝病进展的影响。
  • 对MASLD合并高血压患者,可考虑将无创纤维化评估纳入常规诊疗以促进早期风险分层和针对性干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hypertension is common in metabolic dysfunction-associated steatotic liver disease (MASLD), but its impact on long-term clinical outcomes and disease progression remains unclear. This study investigated the association of hypertension with the risk of adverse clinical outcomes and progression of liver stiffness/fibrosis in MASLD. METHODS: Three multicenter large cohorts were analyzed: the UK Biobank (UKBB) cohort to assess the risk of adverse clinical outcomes, the VCTE-Prognosis cohort to assess liver stiffness/fibrosis progression, and the Paired Liver Biopsy cohort to assess histologic liver fibrosis progression. Adverse clinical outcomes were defined as all-cause mortality, cardiovascular events, and/or liver-related events. Liver stiffness progression was defined as an increase in liver stiffness measurement from <10 kPa to ≥10 kPa or an increase of ≥20% for baseline liver stiffness measurement ≥10 kPa. Liver fibrosis progression was defined as a 1-stage fibrosis stage increase. Cox regression and Kaplan-Meier analyses were used to evaluate the impact of baseline hypertension on outcomes. RESULTS: A total of 107,316 adults from the UKBB cohort, 8,169 from the VCTE-Prognosis cohort, and 1,670 from the Paired Liver Biopsy cohort were included. The prevalence of hypertension was 37.1%, 33.4%, and 48.9%, respectively. In the UKBB cohort, hypertension was associated with long-term adverse clinical outcomes (adjusted hazard ratio [HR] 1.30, 95% CI 1.26-1.33, p <0.001). In the VCTE-Prognosis cohort, hypertension was associated with a higher risk of liver stiffness progression (adjusted HR 1.57, 95% CI 1.30-1.90, p <0.001), while in the Paired Liver Biopsy cohort, hypertension was associated with a greater risk of histologic liver fibrosis progression (adjusted HR 1.41, 95% CI 1.12-1.78, p = 0.004). Subgroup and sensitivity analyses supported these findings. CONCLUSIONS: Hypertension is a modifiable risk factor that increases the risk of adverse clinical outcomes and progression of liver stiffness and fibrosis in MASLD. IMPACT AND IMPLICATIONS: This study provides robust evidence from three large multicenter cohorts demonstrating that hypertension is independently associated with increased risks of adverse clinical outcomes and liver fibrosis progression in individuals with MASLD. These findings reveal that hypertension, traditionally managed from a cardiovascular perspective, also plays a critical and underrecognized role in liver disease progression, making them highly relevant for hepatologists, cardiologists, and primary care providers. Incorporating non-invasive fibrosis assessments into routine care for patients with MASLD and hypertension may facilitate early risk stratification and support targeted interventions to reduce both hepatic and cardiovascular complications.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhou XD, Lian LY, Chen QF, et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol. 2025. PMID: 40854336. doi:10.1016/j.jhep.2025.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。